Day One is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. Initially, the Company has focused its clinical development efforts on pediatric patients. The Company’s lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is being evaluated in a Phase 2 trial.